Picton Mahoney Asset Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

Picton Mahoney Asset Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$830	Hold	50,000	–	–	﹤0.01%	1194
2025 Q4	$825	Hold	50,000	–	–	﹤0.01%	1161
2025 Q3	$1K	Hold	50,000	–	–	﹤0.01%	1058
2025 Q2	$1K	Hold	50,000	–	–	﹤0.01%	958
2025 Q1	$3K	Hold	50,000	–	–	﹤0.01%	676
2024 Q4	$3K	Hold	50,000	–	–	﹤0.01%	579
2024 Q3	$1K	Hold	50,000	–	–	﹤0.01%	832
2024 Q2	$1K	Hold	50,000	–	–	﹤0.01%	593
2024 Q1	$1K	Hold	50,000	–	–	﹤0.01%	367
2023 Q4	$3K	Hold	50,000	–	–	﹤0.01%	414
2023 Q3	$3K	Hold	50,000	–	–	﹤0.01%	401
2023 Q2	$3K	Sell	50,000 -25,000	-33%	-$918	﹤0.01%	409
2023 Q1	$3K	Hold	75,000	–	–	﹤0.01%	476
2022 Q4	$5K	Hold	75,000	–	–	﹤0.01%	591
2022 Q3	$9K	Hold	75,000	–	–	﹤0.01%	640
2022 Q2	$12K	Buy	+75,000	New	+$16.3K	﹤0.01%	743

Other funds holding ASBPW

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Picton Mahoney Asset Management's ASBPW Position: Q1 2026 in Review

Picton Mahoney Asset Management held its Aspire Biopharma Warrant (ASBPW) position steady in Q1 2026 at 50,000 shares worth $830. The position accounts for ﹤0.01% of the portfolio, ranked #1194.

Picton Mahoney Asset Management first reported a position in ASBPW in Q2 2022 and has held it in 16 quarters since. The position peaked at $12K in Q2 2022. 29 funds tracked by Wall St. Rank hold ASBPW as of Q1 2026.

Picton Mahoney Asset Management held 50,000 shares of Aspire Biopharma Warrant worth $830 as of Q1 2026.
Picton Mahoney Asset Management left its Aspire Biopharma Warrant share count unchanged in Q1 2026.
Aspire Biopharma Warrant made up ﹤0.01% of Picton Mahoney Asset Management's portfolio in Q1 2026, its #1194 holding.
Picton Mahoney Asset Management first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 16 quarters since.
Picton Mahoney Asset Management's Aspire Biopharma Warrant position peaked at $12K in Q2 2022.
29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2026, filed 13 May 2026.